Last reviewed · How we verify
Prednisone and Belimumab
Prednisone suppresses immune responses through glucocorticoid receptor activation, while belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cell survival and antibody production.
Prednisone suppresses immune responses through glucocorticoid receptor activation, while belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cell survival and antibody production. Used for Systemic lupus erythematosus (SLE).
At a glance
| Generic name | Prednisone and Belimumab |
|---|---|
| Also known as | Belimumab treatment |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Corticosteroid + Monoclonal antibody (BLyS inhibitor) |
| Target | Glucocorticoid receptor (prednisone); BLyS/BAFF (belimumab) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Prednisone is a corticosteroid that broadly dampens inflammatory and immune responses by binding glucocorticoid receptors and suppressing cytokine production and immune cell activation. Belimumab is a monoclonal antibody that specifically targets BLyS (also called BAFF), a key survival factor for B cells, thereby reducing pathogenic autoantibody-producing B cells. Together, this combination provides both broad immunosuppression and targeted B cell depletion.
Approved indications
- Systemic lupus erythematosus (SLE)
Common side effects
- Infection
- Immunosuppression-related complications
- Corticosteroid-related side effects (hyperglycemia, osteoporosis, mood changes)
- Infusion reactions (belimumab)
Key clinical trials
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE (PHASE3)
- Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis) (PHASE2)
- Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (PHASE2)
- Belimumab Treatment for IgG4-related Disease (PHASE4)
- Rituximab and Belimumab for Lupus Nephritis (PHASE2)
- Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone and Belimumab CI brief — competitive landscape report
- Prednisone and Belimumab updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI